- Home
- TXMD vs IMNN Comparison
TXMD vs IMNN Comparison
Compare TXMD & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- IMNN
- Stock Information
- Founded
- TXMD 2008
- IMNN 1982
- Country
- TXMD United States
- IMNN United States
- Employees
- TXMD N/A
- IMNN N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- IMNN Health Care
- Exchange
- TXMD Nasdaq
- IMNN Nasdaq
- Market Cap
- TXMD 12.3M
- IMNN 12.9M
- IPO Year
- TXMD N/A
- IMNN 1985
- Fundamental
- Price
- TXMD N/A
- IMNN $5.33
- Analyst Decision
- TXMD
- IMNN Buy
- Analyst Count
- TXMD 0
- IMNN 2
- Target Price
- TXMD N/A
- IMNN $182.61
- AVG Volume (30 Days)
- TXMD 16.0K
- IMNN 153.1K
- Earning Date
- TXMD 11-11-2025
- IMNN 11-06-2025
- Dividend Yield
- TXMD N/A
- IMNN N/A
- EPS Growth
- TXMD N/A
- IMNN N/A
- EPS
- TXMD N/A
- IMNN N/A
- Revenue
- TXMD $2,559,000.00
- IMNN N/A
- Revenue This Year
- TXMD $427.09
- IMNN N/A
- Revenue Next Year
- TXMD N/A
- IMNN N/A
- P/E Ratio
- TXMD N/A
- IMNN N/A
- Revenue Growth
- TXMD 156.93
- IMNN N/A
- 52 Week Low
- TXMD $0.70
- IMNN $4.70
- 52 Week High
- TXMD $2.44
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- TXMD 44.55
- IMNN 47.96
- Support Level
- TXMD $0.99
- IMNN $5.04
- Resistance Level
- TXMD $1.11
- IMNN $5.55
- Average True Range (ATR)
- TXMD 0.03
- IMNN 0.29
- MACD
- TXMD 0.00
- IMNN 0.04
- Stochastic Oscillator
- TXMD 57.85
- IMNN 70.94
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).